Vanguard Group Inc. Raises Stock Holdings in Fulgent Genetics, Inc. (NASDAQ:FLGT)

Vanguard Group Inc. raised its position in shares of Fulgent Genetics, Inc. (NASDAQ:FLGT) by 0.2% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,393,711 shares of the company’s stock after purchasing an additional 3,139 shares during the quarter. Vanguard Group Inc. owned 4.70% of Fulgent Genetics worth $37,268,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Covington Capital Management increased its holdings in shares of Fulgent Genetics by 133.3% in the third quarter. Covington Capital Management now owns 700 shares of the company’s stock valued at $27,000 after purchasing an additional 400 shares during the period. Geneos Wealth Management Inc. increased its holdings in shares of Fulgent Genetics by 416.8% in the first quarter. Geneos Wealth Management Inc. now owns 491 shares of the company’s stock valued at $30,000 after purchasing an additional 396 shares during the period. Asset Management One Co. Ltd. acquired a new position in shares of Fulgent Genetics in the third quarter valued at about $34,000. Covestor Ltd increased its holdings in shares of Fulgent Genetics by 48.0% in the third quarter. Covestor Ltd now owns 1,508 shares of the company’s stock valued at $40,000 after purchasing an additional 489 shares during the period. Finally, Lazard Asset Management LLC acquired a new position in shares of Fulgent Genetics in the fourth quarter valued at about $46,000. 48.06% of the stock is owned by institutional investors and hedge funds.

Fulgent Genetics Stock Down 3.2 %

Fulgent Genetics stock opened at $21.16 on Thursday. The firm has a market cap of $632.68 million, a price-to-earnings ratio of -3.75 and a beta of 1.43. Fulgent Genetics, Inc. has a 52 week low of $20.69 and a 52 week high of $44.09. The business’s 50-day moving average price is $23.30 and its 200 day moving average price is $25.66.

Fulgent Genetics (NASDAQ:FLGT) last posted its earnings results on Wednesday, February 28th. The company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.63) by $0.61. The firm had revenue of $70.51 million for the quarter, compared to analyst estimates of $67.14 million. Fulgent Genetics had a negative return on equity of 3.04% and a negative net margin of 58.03%. Equities analysts expect that Fulgent Genetics, Inc. will post -2.04 EPS for the current year.

Analyst Ratings Changes

Separately, Piper Sandler cut their price objective on Fulgent Genetics from $28.00 to $25.00 and set a “neutral” rating on the stock in a report on Wednesday, March 6th.

Fulgent Genetics Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.